title: Effects of memantine on cerebrospinal fluid biomarkers of neurofibrillary pathology.
abstract: Previous studies showed that memantine inhibits tau hyperphosphorylation in vitro. In this study, phosphorylated tau (P-tau) and total tau (T-tau) were measured before and after 6 month treatment with memantine in 12 subjects ranging from normal cognition with subjective memory complaints, through mild cognitive impairment to mild Alzheimer's disease. Thirteen non-treated individuals served as controls. Treatment was associated with a reduction of P-tau in subjects with normal cognition. No treatment effects were seen among impaired individuals, suggesting that longer treatment time may be necessary to achieve biomarker effect in this group.
authors: Center for Brain Health, Department of Psychiatry, New York University School of Medicine, 145 East 32nd Street, 5th Floor, New York, NY10016, USA. Lidia.Glodzik-Sobanska@nyumc.org
authors: Lidia
authors: L
authors: Glodzik
authors: Susan
authors: S
authors: De Santi
authors: Kenneth E
authors: KE
authors: Rich
authors: Miroslaw
authors: M
authors: Brys
authors: Elizabeth
authors: E
authors: Pirraglia
authors: Rachel
authors: R
authors: Mistur
authors: Remigiusz
authors: R
authors: Switalski
authors: Lisa
authors: L
authors: Mosconi
authors: Martin
authors: M
authors: Sadowski
authors: Henrik
authors: H
authors: Zetterberg
authors: Kaj
authors: K
authors: Blennow
authors: Mony J
authors: MJ
authors: de Leon
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid / Q000188:drug therapy / Q000473:pathology; D000978:Antiparkinson Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D015415:Biomarkers / Q000134:cerebrospinal fluid; D001921:Brain / Q000473:pathology*; D003072:Cognition Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D008559:Memantine / Q000494:pharmacology* / Q000627:therapeutic use*; D016874:Neurofibrillary Tangles / Q000473:pathology*; D009483:Neuropsychological Tests; D010766:Phosphorylation / Q000187:drug effects; D012720:Severity of Illness Index; D013129:Spinal Puncture; D016875:tau Proteins / Q000378:metabolism
chemical_list: D000978:Antiparkinson Agents; D015415:Biomarkers; D016875:tau Proteins; D008559:Memantine